warm to touch; itching; redness expanding circle (L); swelling; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE ERYTHEMA (redness expanding circle (L)), VACCINATION SITE PRURITUS (itching), VACCINATION SITE SWELLING (swelling) and VACCINATION SITE WARMTH (warm to touch) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012L20A) for COVID-19 vaccination.     The patient's past medical history included Allergy to vaccine (Allergy to shingles vaccine) since an unknown date and Hypersensitivity.    On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Jan-2021, the patient experienced VACCINATION SITE SWELLING (swelling). On 15-Jan-2021, the patient experienced VACCINATION SITE ERYTHEMA (redness expanding circle (L)). On 20-Jan-2021, the patient experienced VACCINATION SITE PRURITUS (itching). On 21-Jan-2021, the patient experienced VACCINATION SITE WARMTH (warm to touch). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) ongoing since an unknown date for product used for unknown indication, at an unspecified dose and frequency and ASPIRIN [ACETYLSALICYLIC ACID] ongoing since an unknown date at a dose of UNK UNK, qid. On 16-Jan-2021, VACCINATION SITE SWELLING (swelling) outcome was unknown. At the time of the report, VACCINATION SITE ERYTHEMA (redness expanding circle (L)), VACCINATION SITE PRURITUS (itching) and VACCINATION SITE WARMTH (warm to touch) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Patient received treatment including Ice pack.  Concomitant medication was not reported. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 26-Jan-2021 and was forwarded to Moderna on 26-Jan-2021.    This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE ERYTHEMA (redness expanding circle (L)), VACCINATION SITE PRURITUS (itching), VACCINATION SITE SWELLING (swelling) and VACCINATION SITE WARMTH (warm to touch) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012L20A) for COVID-19 vaccination.     The patient's past medical history included Allergy to vaccine (Allergy to shingles vaccine) since an unknown date and Hypersensitivity.    On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Jan-2021, the patient experienced VACCINATION SITE SWELLING (swelling). On 15-Jan-2021, the patient experienced VACCINATION SITE ERYTHEMA (redness expanding circle (L)). On 20-Jan-2021, the patient experienced VACCINATION SITE PRURITUS (itching). On 21-Jan-2021, the patient experienced VACCINATION SITE WARMTH (warm to touch). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) ongoing since an unknown date for product used for unknown indication, at an unspecified dose and frequency and ASPIRIN [ACETYLSALICYLIC ACID] ongoing since an unknown date at a dose of UNK UNK, qid. On 16-Jan-2021, VACCINATION SITE SWELLING (swelling) outcome was unknown. At the time of the report, VACCINATION SITE ERYTHEMA (redness expanding circle (L)), VACCINATION SITE PRURITUS (itching) and VACCINATION SITE WARMTH (warm to touch) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Patient received treatment including Ice pack.  Concomitant medication was not reported.